Get the Stockscreener App
1.49
1.36%
0.02
Galmed Pharmaceuticals Ltd stock is traded at $1.49, with a volume of 146.21K.
It is up +1.36% in the last 24 hours and down -15.82% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.47
Open:
$1.45
24h Volume:
146.21K
Relative Volume:
0.50
Market Cap:
$8.14M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4571
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
+3.47%
1M Performance:
-15.82%
6M Performance:
-44.88%
1Y Performance:
-63.91%
1-Day Range:
$1.4102
$1.52
1-Week Range:
$1.35
$1.59
52-Week Range:
$1.15
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.49 | 8.46M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Applying chart zones and confluence areas to Galmed Pharmaceuticals Ltd.Market Activity Recap & Free Fast Gain Swing Trade Alerts - Newser
Has Galmed Pharmaceuticals Ltd. found a price floor2025 Top Decliners & Safe Capital Growth Trade Ideas - Newser
How moving averages guide Galmed Pharmaceuticals Ltd. trading2025 Market Sentiment & Free Safe Capital Growth Stock Tips - Newser
Is Galmed Pharmaceuticals Ltd. meeting your algorithmic filter criteriaTrade Risk Report & Free Long-Term Investment Growth Plans - Newser
Using data tools to time your Galmed Pharmaceuticals Ltd. exitCEO Change & Smart Allocation Stock Reports - Newser
Is it time to cut losses on Galmed Pharmaceuticals Ltd.GDP Growth & Daily Entry Point Trade Alerts - Newser
Using portfolio simulators with Galmed Pharmaceuticals Ltd. includedQuarterly Earnings Summary & Weekly Momentum Stock Picks - Newser
Can Galmed Pharmaceuticals Ltd. hit a new high this monthJuly 2025 Spike Watch & Long-Term Investment Growth Plans - Newser
Identifying reversal signals in Galmed Pharmaceuticals Ltd.Portfolio Return Summary & Safe Capital Growth Stock Tips - Newser
What’s next for Galmed Pharmaceuticals Ltd. stock price2025 Institutional Moves & AI Powered Buy and Sell Recommendations - Newser
Published on: 2025-08-19 06:00:41 - Newser
Volatility clustering patterns for Galmed Pharmaceuticals Ltd.July 2025 Update & Consistent Return Strategy Ideas - Newser
Galmed Pharmaceuticals' Share Offering: Weighing Dilution Risks Against High-Stakes Biopharma Growth - AInvest
Intraday Charts Show Spike in Galmed Pharmaceuticals Ltd. ActivityJuly 2025 Movers & Weekly Momentum Picks - newsimpact.co.kr
Why Galmed Pharmaceuticals Ltd. is moving todayJuly 2025 Volume & Consistent Profit Trading Strategies - Newser
How Galmed Pharmaceuticals Ltd. stock performs during market volatilityJobs Report & Verified Chart Pattern Signals - Newser
How to recover losses in Galmed Pharmaceuticals Ltd. stockTrend Reversal & Daily Technical Forecast Reports - Newser
Technical signs of recovery in Galmed Pharmaceuticals Ltd.Market Sentiment Report & Real-Time Volume Analysis - Newser
Historical volatility pattern of Galmed Pharmaceuticals Ltd. visualizedQuarterly Trade Summary & Long-Term Capital Growth Strategies - Newser
Does Galmed Pharmaceuticals Ltd. have strong fundamentalsRate Hike & High Conviction Buy Zone Picks - thegnnews.com
Is Galmed Pharmaceuticals Ltd. showing signs of accumulationQuarterly Market Review & Stepwise Trade Execution Plans - Newser
What machine learning models say about Galmed Pharmaceuticals Ltd.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
What makes Galmed Pharmaceuticals Ltd. stock price move sharplyQuarterly Growth Report & Reliable Trade Execution Plans - thegnnews.com
Analyzing Galmed Pharmaceuticals Ltd. with multi timeframe chartsTrade Risk Summary & Free High Return Stock Watch Alerts - Newser
Is Galmed Pharmaceuticals Ltd. still worth holding after the dipGlobal Markets & Entry Point Confirmation Signals - Newser
Is Galmed Pharmaceuticals Ltd. Stock a Good Fit for Conservative Investors2025 Biggest Moves & Real-Time Sentiment Analysis - Newser
Galmed Pharmaceuticals Amends Articles of Association Following Shareholder Approval - TipRanks
Galmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of Quorum - TipRanks
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):